XBI ETF holdings (NYSE) - Page 7 | MetaTrader

Abrir gráfico completo Full chart

Visão geral Todos os ativos Mapa de calor

Principais ativos Market Value Shares Weight %

MYGN Myriad Genetics Inc 15.2 M 2.5 M 0.2%

IMRX Immuneering Corp 14.3 M 2.2 M 0.2%

RGNX REGENXBIO Inc 14.1 M 980.9 K 0.2%

CMPX Compass Therapeutics Inc 13.5 M 2.5 M 0.2%

VIR Vir Biotechnology Inc 13.4 M 2.2 M 0.2%

AKBA Akebia Therapeutics Inc 13.3 M 8.3 M 0.2%

PRTA Prothena Corp PLC 13.1 M 1.4 M 0.2%

CRVS Corvus Pharmaceuticals Inc 12.7 M 1.7 M 0.2%

ABSI Absci Corp 11.8 M 3.4 M 0.2%

ANNX Annexon Inc 11.8 M 2.3 M 0.2%

ALT Altimmune Inc 11.7 M 3.2 M 0.1%

IVVD Invivyd Inc 11.6 M 4.7 M 0.1%

INBX Inhibrx Biosciences Inc 11.2 M 142.2 K 0.1%

PRME Prime Medicine Inc 10.8 M 3.1 M 0.1%

CGEM Cullinan Therapeutics Inc 10.6 M 1.0 M 0.1%

FDMT 4D Molecular Therapeutics Inc 10.4 M 1.4 M 0.1%

KROS Keros Therapeutics Inc 10.2 M 501.7 K 0.1%

AVBP ArriVent Biopharma Inc 9.6 M 478.4 K 0.1%

ABUS Arbutus Biopharma Corp 9.3 M 1.9 M 0.1%

AVXL Anavex Life Sciences Corp 9.2 M 2.6 M 0.1%

1
2
3
4
5
6
7
8

Notícias

First Quarter Earnings: Sharpening Sector Divergence

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

3 Reasons To Stick With Growth Stocks In Rotating Markets

Seeking Innovation Beyond Tech? Insight On Healthcare Stocks

Biotech Investors Are Tuning Out the MAHA Chaos

Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)

Preço-alvo da Capricor mantido em US$ 63 pela B.Riley com avanços na FDA

FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint

Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)

Juros a descoberto da Intellia lideram alta entre biotechs, diz Baird

Mizuho reduz preço-alvo da Immunocore para US$ 34 após revisão de receita